Medical insurance drugs are based on the national basic medical insurance drug catalog, and adhere to the clinically necessary, safe and effective, reasonable price, convenient use, market can guarantee the supply and medical insurance can afford the drugs. In 2019, the negotiation on the access of drugs for national medical insurance has been completed, and 97 drugs have been successfully negotiated for 150 drugs, all of which are included in the scope of category B drugs in the catalogue. Among them, 70 of the 119 new drugs were negotiated successfully, with an average price drop of 60.7%.
Xiong Xianjun, director of the medical service management department of the State Medical Insurance Bureau, said that the negotiation on the access of national medical insurance drugs in 2019 had been completed, and the adjustment of the national directory of drugs for basic medical insurance, work injury insurance and maternity insurance in 2019 had been completed in an all-round way. In the regular access stage of medical insurance drug catalogue, 128 alternative lists of negotiated drugs were proposed by experts' review and voting, and 119 drugs were finally determined as new negotiated varieties. In addition, 31 of the drugs negotiated for access in 2017 need to be renegotiated for renewal. The total number of new negotiated drugs and the total amount of negotiated drugs reached a record high.
Specifically, of the 150 negotiated drugs, 97 were negotiated, all of which were included in the category B drug list. Among them, 70 of the 119 new drugs were negotiated successfully, with an average price drop of 60.7%. The average decrease rate of three kinds of hepatitis C treatment drugs is more than 85%, and the average decrease rate of cancer, diabetes and other treatment drugs is about 65%. 27 of the 31 renewed drugs were successful, with an average price drop of 26.4%.
Most of the drugs successfully negotiated in this negotiation are newly marketed drugs with high clinical value in recent years, involving more than 10 clinical treatment fields such as cancer, rare disease, hepatitis, diabetes, MDR-TB, rheumatism immunity, cardio cerebrovascular, digestion, etc. From the perspective of key areas, all 5 basic drugs were negotiated successfully, 22 anticancer drugs, 7 drugs for rare diseases, 14 drugs for chronic diseases (including diabetes, hepatitis B, rheumatoid arthritis, etc.), 4 drugs for children were negotiated successfully, and the directory structure was further optimized.
Through regular access and negotiation access, 2709 drugs were included in the national directory of basic medical insurance, work injury insurance and maternity insurance drugs in 2019. Compared with the 2017 version, 218 drugs were transferred in, 154 drugs were transferred out, a net increase of 64.
According to reports, by giving play to the role of "strategic buyers" in the medical insurance sector, the drug cost has been greatly reduced by exchanging quantity for price. Many famous "noble drugs" in the world offer "civilian price", and the imported drugs basically offer the lowest price in the world. It is estimated that through negotiation of price reduction and medical insurance reimbursement, the individual burden of patients will be reduced to less than 20% of the original level, and the individual drugs will be reduced to less than 5%.
Disclaimer: This article is reproduced for the purpose of transmitting more information. If there is a source marking error or infringing your legitimate rights and interests, please contact our website with the ownership certificate. We will correct and delete it in time. Thank you.